166 related articles for article (PubMed ID: 8707771)
1. The use of serologic tumor markers in gastrointestinal malignancies.
Posner MR; Mayer RJ
Hematol Oncol Clin North Am; 1994 Jun; 8(3):533-53. PubMed ID: 8707771
[TBL] [Abstract][Full Text] [Related]
2. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Haglund C
Anticancer Res; 2002; 22(4):2311-6. PubMed ID: 12174919
[TBL] [Abstract][Full Text] [Related]
3. [The clinical information value of an immunoenzyme study of the tumor markers CA-19-9, CEA and AFP in cancer of the stomach, pancreas, colon and rectum].
Ial'chenko NA; Lagutin VD; Lavik NN; Musin II
Vopr Onkol; 1991; 37(9-10):921-4. PubMed ID: 1726842
[TBL] [Abstract][Full Text] [Related]
4. [Gastrointestinal cancer].
Takahashi Y
Gan To Kagaku Ryoho; 2004 Aug; 31(8):1275-9. PubMed ID: 15332558
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of serum tumor markers in asymptomatic individuals.
Eleftheriadis N; Papaloukas C; Pistevou-Gompaki K
J BUON; 2009; 14(4):707-10. PubMed ID: 20148467
[TBL] [Abstract][Full Text] [Related]
6. [Antigens (CEA and CA 19-9) in diagnosis and prognosis colorectal cancer].
Grotowski M
Pol Merkur Lekarski; 2002 Jan; 12(67):77-80. PubMed ID: 11957811
[TBL] [Abstract][Full Text] [Related]
7. CA 242 in comparison with established tumour markers in colorectal, pancreatic and lung cancer.
Hasholzner U; Stieber P; Reiter W; Zimmermann A; Hofmann K; Schalhorn A
Anticancer Res; 1999; 19(4A):2477-80. PubMed ID: 10470177
[TBL] [Abstract][Full Text] [Related]
8. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
9. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
11. [Tumor markers in cancer of the digestive system].
Zinser JW
Rev Gastroenterol Mex; 1997; 62(3):145-8. PubMed ID: 9480520
[TBL] [Abstract][Full Text] [Related]
12. [Standards, options and recommendations for tumor markers in colorectal cancer].
Eche N; Pichon MF; Quillien V; Gory-Delabaere G; Riedinger JM; Basuyau JP; Daver A; Buecher B; Conroy T; Dieu L; Bidart JM; Deneux L;
Bull Cancer; 2001 Dec; 88(12):1177-206. PubMed ID: 11792611
[TBL] [Abstract][Full Text] [Related]
13. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
14. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers.
Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J
Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125
[TBL] [Abstract][Full Text] [Related]
15. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
16. CA 242--a step ahead.
Shahi SK; Ranga S; Bhullar C
Indian J Pathol Microbiol; 2002 Apr; 45(2):145-6. PubMed ID: 12696727
[No Abstract] [Full Text] [Related]
17. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer.
Locker GY; Hamilton S; Harris J; Jessup JM; Kemeny N; Macdonald JS; Somerfield MR; Hayes DF; Bast RC;
J Clin Oncol; 2006 Nov; 24(33):5313-27. PubMed ID: 17060676
[TBL] [Abstract][Full Text] [Related]
18. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer.
Griesenberg D; Nürnberg R; Bahlo M; Klapdor R
Anticancer Res; 1999; 19(4A):2443-50. PubMed ID: 10470173
[TBL] [Abstract][Full Text] [Related]
19. [Value of serologic markers in the management of colorectal cancer].
Wainstein RC; Milano MC
Acta Gastroenterol Latinoam; 1995; 25(5):309-10. PubMed ID: 8733259
[No Abstract] [Full Text] [Related]
20. Normal and modified urinary nucleosides represent novel biomarkers for colorectal cancer diagnosis and surgery monitoring.
Feng B; Zheng MH; Zheng YF; Lu AG; Li JW; Wang ML; Ma JJ; Xu GW; Liu BY; Zhu ZG
J Gastroenterol Hepatol; 2005 Dec; 20(12):1913-9. PubMed ID: 16336453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
